The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data


Variant: NM_001754.5(RUNX1):c.601dup (p.Arg201fs)

CA913189266

1073884 (ClinVar)

Gene: RUNX1
Condition: hereditary thrombocytopenia and hematologic cancer predisposition syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: 808f09c3-3f62-4523-b5b4-ede068a28f23
Approved on: 2023-12-09
Published on: 2023-12-09

HGVS expressions

NM_001754.5:c.601dup
NM_001754.5(RUNX1):c.601dup (p.Arg201fs)
NC_000021.9:g.34859489dup
CM000683.2:g.34859489dup
NC_000021.8:g.36231786dup
CM000683.1:g.36231786dup
NC_000021.7:g.35153656dup
NG_011402.2:g.1130226dup
ENST00000675419.1:c.601dup
ENST00000300305.7:c.601dup
ENST00000344691.8:c.520dup
ENST00000358356.9:c.520dup
ENST00000399237.6:c.565dup
ENST00000399240.5:c.520dup
ENST00000437180.5:c.601dup
ENST00000467577.1:n.93dup
ENST00000482318.5:c.*191dup
NM_001001890.2:c.520dup
NM_001122607.1:c.520dup
NM_001754.4:c.601dup
NM_001001890.3:c.520dup
NM_001122607.2:c.520dup
More

Pathogenic

Met criteria codes 4
PM5_Supporting PS4_Supporting PM2_Supporting PVS1
Not Met criteria codes 22
BP4 BP3 BP1 BP2 BP5 BP7 PS1 PS2 PS3 PP1 PP2 PP3 PP4 PM1 PM3 BA1 PM4 PM6 BS2 BS1 BS4 BS3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Myeloid Malignancy VCEP
NM_001754.5(RUNX1):c.601dup (p.Arg201ProfsTer12) is a frameshift variant. The transcript product is predicted to undergo NMD (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 in gnomAD v2.1.1 and v3.1.2 (PM2_supporting). This variant has been reported in 1 proband with family history meeting RUNX-1 phenotypic criteria (thrombocytopenia) (PMID 26175287) (PS4_supporting). This variant was also reported in Clinvar in 2021 by Invitae but the affected status of the proband is unknown (Variation ID 1073884). There are 25 nonsense/frameshift variants classified as pathogenic by the MM-VCEP in exons 3-7 (two per exon) without use of PM5_Supporting (PMID: 35764482) (PM5_supporting). In summary, the clinical significance of this variant is pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PS4_supporting, PM2_supporting, PM5_supporting.
Met criteria codes
PM5_Supporting
There are 25 nonsense/frameshift variants classified as pathogenic by the MM-VCEP in exons 3-7 (two per exon) without use of PM5_Supporting (PMID: 35764482). This frameshift variant is downstream c.98.
PS4_Supporting
This variant has been reported in 1 proband with family history meeting RUNX-1 phenotypic criteria (thrombocytopenia) ](PS4_Supporting]; PMID 26175287. This variant was also reported in Clinvar in 2021 by Invitae but the affected status of the proband is unknown (Variation ID 1073884).
PM2_Supporting
This variant is completely absent from all population databases with at least 20x coverage for RUNX1 in gnomAD v2.1.1 and v3.1.2 (PM2_supporting).
PVS1
The transcript product of this frameshift variant is predicted to undergo NMD.
Not Met criteria codes
BP4
This variant is a loss-of-function variant.
BP3
This variant is a frameshift.
BP1
This rule is not applicable to the MMVCEP.
BP2
No information found in the literature.
BP5
This rule is not applicable to the MMVCEP
BP7
This variant is a loss-of-function variant.
PS1
This variant is a loss-of-function variant.
PS2
There is no proof of testing of other affected family members (PMID 26175287).
PS3
To our knowledge, this synonymous variant was not evaluated in transactivation assays. However, p.(Arg201*) was used in Decker et al functional study as a positive pathogenic control has been shown to be damaging.
PP1
There is no proof of testing of other affected family members (PMID 26175287).
PP2
This variant is a loss-of-function variant.
PP3
This variant is a loss-of-function variant.
PP4
This rule is not applicable to the MMVCEP.
PM1
This variant is not a missense.
PM3
This rule is not applicable for MM-VCEP.
BA1
This variant is completely absent from all population databases with at least 20x coverage for RUNX1 in gnomAD v2.1.1 and v3.1.2 (PM2_supporting).
PM4
This variant is a frameshift.
PM6
There is no proof of testing of other affected family members (PMID 26175287).
BS2
This rule is not applicable to the MMVCEP.
BS1
This variant is completely absent from all population databases with at least 20x coverage for RUNX1 in gnomAD v2.1.1 and v3.1.2 (PM2_supporting).
BS4
There is no proof of testing of other affected family members (PMID 26175287).
BS3
To our knowledge, this synonymous variant was not evaluated in transactivation assays. However, p.(Arg201*) was used in Decker et al functional study as a positive pathogenic control has been shown to be damaging.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.